Cargando…
PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1)
Liver dysfunction is an outstanding dose-limiting toxicity of gefitinib, an EGFR (epidermal growth factor receptor)-tyrosine kinase inhibitor (TKI), in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). We aimed to elucidate the mechanisms underlying gefitinib-induced hepato...
Autores principales: | Luo, Peihua, Yan, Hao, Du, Jiangxia, Chen, Xueqin, Shao, Jinjin, Zhang, Ying, Xu, Zhifei, Jin, Ying, Lin, Nengming, Yang, Bo, He, Qiaojun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526032/ https://www.ncbi.nlm.nih.gov/pubmed/33315519 http://dx.doi.org/10.1080/15548627.2020.1851492 |
Ejemplares similares
-
Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1
por: Xu, Li, et al.
Publicado: (2017) -
Computational Design of Targeted Inhibitors of Polo-Like Kinase 1 (Plk1)
por: Jani, Krupa S., et al.
Publicado: (2012) -
Polo-like kinase 1 (Plk1): an Unexpected Player in DNA Replication
por: Song, Bing, et al.
Publicado: (2012) -
Role of Polo-like Kinases Plk1 and Plk4 in the Initiation of Centriole Duplication—Impact on Cancer
por: Hoffmann, Ingrid
Publicado: (2022) -
PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy
por: Ruf, Stefanie, et al.
Publicado: (2017)